SB1223

Missouri SB1223 mandates disclosure for products with gene therapy potential and requires informed consent for exposure.

Missouri SB1223 amends Chapter 196 by adding sections requiring disclosure for products with gene therapy potential. These products must provide information on exposure risks and obtain informed consent from individuals who could be exposed. The bill defines "gene therapy product" as any product with the capacity to alter genetic material, including vaccines, drugs, and medical interventions. Manufacturers, government agencies, and organizations involved in producing, selling, or distributing these products must comply with the disclosure requirements.